Synthetic DNA powers next-generation gene therapy trial

A clinical study in the United States has begun using a novel form of synthetic DNA as a key ingredient in the manufacture of an advanced gene therapy, highlighting a new era in precision biomanufacturing.

The DNA – produced using Touchlight’s enzymatic dbDNA™ platform – replaces traditional plasmid DNA with a cleaner, faster, and more scalable alternative. Its unique linear, closed-ended design eliminates bacterial sequences, delivering a high-purity template ideally suited for gene therapy production.

A senior scientist involved in the trial commented:

“Using the dbDNA platform gave us the quality and scalability needed to move our program forward quickly. The production process was responsive and technically strong, and the DNA batches met every specification. Communication and support throughout were excellent.”

Unlike conventional plasmid-based manufacturing, dbDNA is created without cells, avoiding issues such as antibiotic resistance and sequence instability. This streamlined, cell-free approach aligns with regulatory priorities for safer, more consistent genetic materials and accelerates timelines for therapeutic development.

The use of dbDNA in this US clinical program follows GMP certification of Touchlight’s Hampton, UK, manufacturing site earlier this year. With its expanding partnerships and technology pipeline, the company is helping to redefine how DNA is made for advanced therapies — supporting scientists and biopharma innovators as they bring life-changing treatments to patients.

More information online